Oct 16 (Reuters) - Sartorius Stedim Biotech SA STDM.PA:
SARTORIUS STEDIM BIOTECH PUBLISHES UNAUDITED RESULTS FOR THE FIRST NINE MONTHS OF 2025
UNDERLYING EBITDA INCREASES 21.0% TO 683 MILLION EUROS; MARGIN 31.1%
SALES REVENUE REACHES 2,195 MILLION EUROS, UP 10.2% IN CONSTANT CURRENCIES
9M UNDERLYING NET PROFIT UP 34.3% TO 320 MILLION EUROS
OUTLOOK: MANAGEMENT SHARPENS FULL-YEAR GUIDANCE AT UPPER END OF RANGE
Source text: nEQ4npcyga
Further company coverage: STDM.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))